Advanced clinical
Decentralized clinical trials are here to stay. Explore both their advantages and their challenges from an operational perspective. Tune in now as experts share their perspectives on:
⦁ The enduring, post-COVID benefits of the decentralized model
⦁ Operational-level challenges
⦁ Sponsor considerations in decentralized trials
⦁ Trial management concerns
⦁ Predictions for the future of decentralized studies
Open Media
Enjoyed this podcast? Find part one here
Advanced clinical
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.